

Electronic Acknowledgement Receipt

EFS ID:	5580046
Application Number:	10559982
International Application Number:	
Confirmation Number:	6583
Title of Invention:	Methods for treatment of parkinson's disease
First Named Inventor/Applicant Name:	Fariello Ruggero
Customer Number:	37509
Filer:	Daniel M. Becker/Paula Hurley
Filer Authorized By:	Daniel M. Becker
Attorney Docket Number:	373987-011US (102895)
Receipt Date:	24-JUN-2009
Filing Date:	02-FEB-2006
Time Stamp:	16:01:32
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$180
RAM confirmation Number	2321
Deposit Account	502778
Authorized User	
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:	
Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part/.zip	Pages (if appl.)				
1		IDS_3.pdf	578820 ce60488134f118f95442988f7f9f319eac34 2d6c	yes	11				
Multipart Description/PDF files in .zip description									
Document Description		Start		End					
Transmittal Letter		1		4					
Information Disclosure Statement (IDS) Filed (SB/08)		5		11					
Warnings:									
Information:									
2	NPL Documents	Andringa_TCH346.pdf	7656602 0ff10794208502ba046eeea30875bcab3 9a8f2	no	13				
Warnings:									
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing									
Information:									
3	NPL Documents	BenedettiAnticonvulsant.pdf	670245 0ff60300a35c0777fbfb98cf2ed22469e8a8 9395	no	6				
Warnings:									
Information:									
4	NPL Documents	Calne_Manganism.pdf	1889043 335cc9862c74b99cd4dc1112e8bc3572f6 d847	no	4				
Warnings:									
Information:									
5	NPL Documents	Chaudhuri_International.pdf	5186140 35255ce32c74062d94cb9a6c9b7ff40 15e6e	no	8				
Warnings:									
Information:									
6	NPL Documents	Chaudhuri_Metric.pdf	7026112 b5d8012a15566055ec32926cbfd7ffbf code	no	11				
Warnings:									
Information:									
7	NPL Documents	Cho_Model.pdf	1594615 907001a0dede4c784de07548fc7220252ca 1299	no	4				

Warnings:					
Information:					
8	NPL Documents	Olanow_CURRICULUM_VITAE.pdf	325321 fba2dfbbdb1464dd0fc54bf977ae94363d a954	no	103
Warnings:					
Information:					
9	NPL Documents	Dubois_Movement.pdf	7631988 52ae5cd9fe007ed34c61794b1a04f29 2299	no	11
Warnings:					
Information:					
10	NPL Documents	Emre_Clinical.pdf	14056640 4e1b6692da71462031eb653c7661f930 55f	no	19
Warnings:					
Information:					
11	NPL Documents	Fahn_Levodopa.pdf	4172282 0561000c5e00fb8a02728289e3a28fc db11	no	11
Warnings:					
Information:					
12	NPL Documents	Freeman_UseofPlacebo.pdf	2440921 bdedaa8073ceec67a05b5-81a512fd773e 4fb7	no	5
Warnings:					
Information:					
13	NPL Documents	Freeman_Bilateral.pdf	4748141 e7089600545ee5b366ed62ae61cad9bc b3985	no	11
Warnings:					
Information:					
14	NPL Documents	Germano_Unilateral.pdf	3895579 6e07ccaa4752085d1bcb02d25ee91f900 61b64	no	8
Warnings:					
Information:					
15	NPL Documents	Goetz_MovementDisorder_Process.pdf	5289205 ec0041cf5edfd7f78acca125b90a0edad2 7616	no	7
Warnings:					
Information:					
16	NPL Documents	Goetz_Sarizotan.pdf	5386115 7e6ffaf5743411b59e6b45e37aa1e509ce 902	no	8

Warnings:					
Information:					
17	NPL Documents	Goetz_MovementDisorder_Scale.pdf	11263322 bd1a1566a1c718ba7a4d78de5e0fb1d0 8621d	no	42
Warnings:					
Information:					
18	NPL Documents	Good_Neuromelanin.pdf	1502116 c504bcc38617179eb7a57ed4db083c853c0 4402b3	no	4
Warnings:					
Information:					
19	NPL Documents	Huang_Progression.pdf	2018295 c9724b1b72941bcf6f1bbdcfe06874db1 15a3	no	6
Warnings:					
Information:					
20	NPL Documents	Hauser_Longterm.pdf	6788693 a101b416664546ec32cb6c1b60e39071 e9fc	no	9
Warnings:					
Information:					
21	NPL Documents	Hauser_Blood.pdf	2395531 513cfaf66702db4599c9db52187ab8ca0 c1a1f	no	5
Warnings:					
Information:					
22	NPL Documents	Jenner_Oxidative.pdf	5299501 381ba318bf61140e31c96ebdf79a24a99254 be0fa	no	11
Warnings:					
Information:					
23	NPL Documents	Koller_High.pdf	2697577 94ae9a0208e12646cc43da20a9e6510 bb0fb	no	8
Warnings:					
Information:					
24	NPL Documents	Kordower_Dopaminergic.pdf	3193845 171c593362bd87e70f0dc870bc70a5143 cd5	no	6
Warnings:					
Information:					
25	NPL Documents	Kordower_FetalGrafting.pdf	2775146 6fa90bd1b1b92262c2d079f9260ed2a3 0d53	no	7

Warnings:					
Information:					
26	NPL Documents	Kordower_Neuropathologic.pdf	3264799 d09c356f85197ab1ef15317df8e472170f1a d4510	no	7
Warnings:					
Information:					
27	NPL Documents	KordowerFunctional.pdf	18722970 dc08ff64e1f0fc24/bde0949326e14fb91 1cd6	no	28
Warnings:					
Information:					
28	NPL Documents	Kordower_FetalNigral.pdf	5404713 fe21d4feef51ca094b412/b665a19fecad cd0	no	11
Warnings:					
Information:					
29	NPL Documents	Kordower_Transplanted.pdf	2050476 ab1b32354c5d890c7e985418654c99423c 9bf0	no	4
Warnings:					
Information:					
30	NPL Documents	Kordower_Lewy.pdf	1683337 6edeb51274a2896ff2dbefbf0fc1fe65c 5416	no	3
Warnings:					
Information:					
31	NPL Documents	Lieberman_Multicenter.pdf	2777346 cea774bb015ba00129723d91dc949cb92 894cb	no	6
Warnings:					
Information:					
32	NPL Documents	Marks_Safety.pdf	6289726 fbc56559ef58fbfa0d8a4d0ed7b1bd4b1911 d0fd	no	9
Warnings:					
Information:					
33	NPL Documents	Martinez_Martin_Prevalence.pdf	4148646 e029ab5c9510d1da1c124a/e52741fa/6 d45	no	7
Warnings:					
Information:					
34	NPL Documents	McNaught_Proteasomal_dyfunction.pdf	6527371 3ebef5b5bfa02941ad594957361BB2 0e644	no	13

Warnings:					
Information:					
35	NPL Documents	McNaught_Impairment_ubiquitin.pdf	2922519 3e5981012ab3aefc0d8feba5cf1d130fb810f8a	no	6
Warnings:					
Information:					
36	NPL Documents	McNaught_Proteasomal_Inhibition_nigral.pdf	2363942 b4c163a4311199b2d64460ec210ect050+4a47457	no	5
Warnings:					
Information:					
37	NPL Documents	McNaught_Systemic_exposure.pdf	6151264 24d26e6137f34270c34d4e5e807bd2e03d67682	no	14
Warnings:					
Information:					
38	NPL Documents	McNaught_Failure_ubiquitin.pdf	4965482 9b42773a52c5d403ed19fc5bf8f0655a0f527	no	6
Warnings:					
Information:					
39	NPL Documents	McNaught_Proteasome_Inhibitor-Induced.pdf	2814972 2eadc05fb1bb6aa1a62765ae15defb05421d66	no	5
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
40	NPL Documents	Morrison_Program.pdf	21334977 64db03b9a054331ded89c1d4122b669757e795c	no	16
Warnings:					
Information:					
41	NPL Documents	Mytilineou_desmethylselegiline.pdf	1952225 09cd01bbdcde7b6dd34b0285e20fd75c	no	3
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
42	NPL Documents	Mytilineou_Inhibition.pdf	4416818 d36067b39bf579df9da3c2a076faa3855649a1	no	15
Warnings:					

Information:					
43	NPL Documents	Nair_p53Mediates.pdf	7850902 494d1bbcc0aae7c8f13ebfe0de975ed0c1a 9ebfe	no	11
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
44	NPL Documents	Olanaow_Free.pdf	898978 961af7901cd8ab9448bc7a8cf0be1f1fd1c e9a05	no	2
Warnings:					
Information:					
45	NPL Documents	Olanow_Double_blind_Bilateral_fetal.pdf	5620996 463b312117bd415cd486ed64295f5011 5b6c5	no	12
Warnings:					
Information:					
46	NPL Documents	Olanow_Role_Deep_Brain.pdf	3804774 5f272cd9907e1ee661b551ea37ca1186c1 9ff0	no	7
Warnings:					
Information:					
47	NPL Documents	Olanow_ClinicalPattern.pdf	3091194 eff0ec1fb2cd3d80854965d3f2f4d38f7 cfd	no	9
Warnings:					
Information:					
48	NPL Documents	Olanow_Fetal_nigral.pdf	3540418 497b0333ea811e904dc08fb8ae6a76ad52d3 b4749	no	8
Warnings:					
Information:					
49	NPL Documents	Olanow_OpenMulticenter.pdf	1415223 3bcb1f796761925e195e30073d301c1e9f1 27a5b	no	6
Warnings:					
Information:					
50	NPL Documents	Olanow_Double_Blind_Pergolide_Sinemet.pdf	2021956 7dd1be53b7111440400d55fcac3sec 95e	no	6
Warnings:					
Information:					

51	NPL Documents	Olanow_Double_blind_controlled_treatment.pdf	2112108 c1359c15a65534c275c3b4093bc360f05fc 4d6c	no	8
----	---------------	--	--	----	---

Warnings:**Information:**

52	NPL Documents	Olanow_Multicenter_double_bind.pdf	2935113 b34a4ca7ff5cc099e18999a7ff1a07 95b	no	8
----	---------------	------------------------------------	--	----	---

Warnings:**Information:**

53	NPL Documents	Olanow_Effect_deprenyl.pdf	2373536 a62009a51c-a616a4c2b4d4810ee7b77a 31e784	no	7
----	---------------	----------------------------	--	----	---

Warnings:**Information:**

54	NPL Documents	Olanow_Tolcapone_hepatotoxic.pdf	4077621 29c52a24916e508e866db11bf5e67cd8 d2cb	no	5
----	---------------	----------------------------------	---	----	---

Warnings:**Information:**

55	NPL Documents	Olanaow_Tolacpone.pdf	2658130 f1af8fa03c73b675e4b42b25e11b520f94 5e1	no	8
----	---------------	-----------------------	--	----	---

Warnings:**Information:**

56	NPL Documents	Olanow_Double_Bland_Placebo-controlled.pdf	4195678 3499010126164b94bd5241c2a2591 3865a	no	6
----	---------------	--	---	----	---

Warnings:**Information:**

57	NPL Documents	Olanow_RandomizedDouble.pdf	4488036 937a785ed8fb5dd932be893e64e46201 872a1	no	8
----	---------------	-----------------------------	--	----	---

Warnings:

The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing

Information:

58	NPL Documents	Parkinson_Study_Group_Effects_Tocopherol.pdf	3616456 963ab411f2640fae4b96d1b6aa22f6113807 e077	no	8
----	---------------	--	---	----	---

Warnings:**Information:**

59	NPL Documents	Olanow_Introduction.pdf	3172091 d4f7ea29d0f052e53c244c73dec36a30e91c 3a08f	no	8
----	---------------	-------------------------	--	----	---

Warnings:					
Information:					
60	Fee Worksheet (PTO-875)	fee-info.pdf	30261 R5903d92119ab9c66164f3c4d7ee997469; BB80	no	2
Warnings:					
Information:					
			Total Files Size (in bytes):	266176849	
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p>New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p>National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p>New International Application Filed with the USPTO as a Receiving Office If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					